Phase 1 data show MP0317 activates tumor immune response safely, advancing to Phase 2 trial in cholangiocarcinoma.

Molecular Partners published Phase 1 data in Nature Cancer showing MP0317, a tumor-localized CD40 agonist, activates immune cells in the tumor microenvironment with a favorable safety profile in advanced cancer patients. The drug anchors to fibroblast activation protein in tumors, potentially improving efficacy and reducing side effects compared to systemic therapies. A Phase 2 trial combining MP0317 with chemotherapy and immunotherapy in cholangiocarcinoma is ongoing to assess clinical benefits. These findings support MP0317's further development in combination cancer treatments.